Outlook Therapeutics OTLK Stock
Outlook Therapeutics Price Chart
Outlook Therapeutics OTLK Financial and Trading Overview
| Outlook Therapeutics stock price | 0.81 USD |
| Previous Close | 0.73 USD |
| Open | 0.74 USD |
| Bid | 0.65 USD x 200 |
| Ask | 1.07 USD x 200 |
| Day's Range | 0.72 - 0.94 USD |
| 52 Week Range | 0.16 - 3.39 USD |
| Volume | 43.66M USD |
| Avg. Volume | 13.21M USD |
| Market Cap | 125.26M USD |
| Beta (5Y Monthly) | 0.333 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.13 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.17 USD |
OTLK Valuation Measures
| Enterprise Value | 121.33M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.1612105 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 375.99377 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 364.193 |
| Enterprise Value/EBITDA | -2.007 |
Trading Information
Outlook Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.333 |
| 52-Week Change | -58.75% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 3.39 USD |
| 52 Week Low | 0.16 USD |
| 50-Day Moving Average | 0.28 USD |
| 200-Day Moving Average | 0.96 USD |
OTLK Share Statistics
| Avg. Volume (3 month) | 13.21M USD |
| Avg. Daily Volume (10-Days) | 61.41M USD |
| Shares Outstanding | 148.59M |
| Float | 105.53M |
| Short Ratio | 1.92 |
| % Held by Insiders | 15.98% |
| % Held by Institutions | 9.16% |
| Shares Short | 9.09M |
| Short % of Float | 7.52% |
| Short % of Shares Outstanding | 7.52% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | September 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -11006.82% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -184.82% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 333.14K USD |
| Revenue Per Share (ttm) | 0.006 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -1202142 USD |
| EBITDA | -60454584 USD |
| Net Income Avi to Common (ttm) | -60956488 USD |
| Diluted EPS (ttm) | -1.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 7.75M USD |
| Total Cash Per Share (mrq) | 0.06 USD |
| Total Debt (mrq) | 27.19M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.538 |
| Book Value Per Share (mrq) | -0.277 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -47045520 USD |
| Levered Free Cash Flow (ttm) | -25471416 USD |
Profile of Outlook Therapeutics
| Country | United States |
| State | NJ |
| City | Iselin |
| Address | 111 S. Wood Avenue |
| ZIP | 08830 |
| Phone | 609 619 3990 |
| Website | https://outlooktherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Q&A For Outlook Therapeutics Stock
What is a current OTLK stock price?
Outlook Therapeutics OTLK stock price today per share is 0.81 USD.
How to purchase Outlook Therapeutics stock?
You can buy OTLK shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Outlook Therapeutics?
The stock symbol or ticker of Outlook Therapeutics is OTLK.
Which industry does the Outlook Therapeutics company belong to?
The Outlook Therapeutics industry is Biotechnology.
How many shares does Outlook Therapeutics have in circulation?
The max supply of Outlook Therapeutics shares is 120.86M.
What is Outlook Therapeutics Price to Earnings Ratio (PE Ratio)?
Outlook Therapeutics PE Ratio is now.
What was Outlook Therapeutics earnings per share over the trailing 12 months (TTM)?
Outlook Therapeutics EPS is -1.13 USD over the trailing 12 months.
Which sector does the Outlook Therapeutics company belong to?
The Outlook Therapeutics sector is Healthcare.
Outlook Therapeutics OTLK included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}